Other articles

Eli Lilly’s Stock Price Drops As Oral GLP-1 Achieves Moderate Weight Loss In Late-Stage Testing

Tern Makes Shift In Pipeline To Cancer Asset TERN-701 As Obesity Space Gets Crowded

BioMarin Gets Rid Of Palynziq Successor To Treat PKU For Lack Of Goal Being Met

Vertex’s Phase 2 Failure Leaves Next-Gen VX-993 Pain Drug On The Chopping Block

Cardiff’s Onvansertib Shows To Be Helpful To RAS-Mutated Colorectal Cancer Patients

Merck’s $3 Billion Cost-Cutting Measure Is First Step For Intended Future Growth

FDA Alters Course On ELEVIDYS Shipping Pause For Ambulatory DMD Patients

CHMP Negative Opinion On ELEVIDYS Brings Further Woes For Sarepta And Its Partner Roche

Rocket Realigns Pipeline Towards Cardiovascular Targeting To Extend Cash Runway

Abivax’s Successful Phase 3 Ulcerative Colitis Trial Shows Obefazimod Differentiation

FDA Rejects Approval Of Replimune’s RP1 For Advanced Melanoma Patients, Type A Meeting Could Possibly Be Next Move

Third Patient Death That Dealt With LGMD Gene Therapy Puts Sarepta’s Pipeline At Risk

Sarepta Establishes Layoffs And siRNA Restructuring With Box Warning Of ELEVIDYS

Kairos Pharma Posts Positive Safety Data With Use Of ENV105 For Advanced Prostate Cancer

AstraZeneca’s Late-Stage Study Win In Treatment Resistant-Hypertension Bolsters Baxdrostat’s Advancement

MiNK Achieves Complete Remission With Allogeneic Off-The-Shelf AgenT-797 In Testicular Cancer Patient

Mereo and Partner Ultragenyx Hit A Stump But Setrusumab For OI Treatment Presses On

To Expand Cardiopulmonary Pipeline Merck Acquires Verona Pharma For $10 Billion

ProKidney Scores Win With Cell Therapy Rilparencel For CKD Patients

Apogee’s IL-13 APG777 Could Challenge Top Contenders In Autoimmune Disorder Targeting Space

Scroll to Top